News
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...
53mon MSN
Healthy Returns: FDA launches program to streamline creation of new U.S. drug manufacturing sites
A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback